CAR T-Cells and Safety Signals

Update: 2024-04-24

Description

This episode examines CAR T-cell therapy’s early successes, broader promise, and emerging risks, as the FDA considers reports of occasional secondary cancers.

A full transcript of this episode is available at nejm.org/doi/full/10.1056/NEJMp2400701.

Comments

In Channel

Brain Injury and Consciousness

2024-09-2525:49

What Exactly Is Long Covid?

2024-09-1126:03

Restoring Lost Speech

2024-08-1422:02

Race-Based Diagnosis, Part 3

2024-07-3125:17

Race-Based Diagnosis, Part 2

2024-07-2423:13

Race-Based Diagnosis, Part 1

2024-07-0327:36

Are We Prepared for Bird Flu?

2024-06-1919:02

Treating Obesity in Kids

2024-06-0525:39

New Hope for a Common and Deadly Heart Condition

2024-05-1524:37

CAR T-Cells and Safety Signals

2024-04-2425:25

Progress for Parkinson's?

2024-04-0326:36

Doctors and Guns

2024-03-1325:38

Race Relations and the First Paramedics

2024-02-2829:06

Why Doctors Need to Talk about Death

2024-02-1423:23

Investigating Injustices in the Journal's History, Part 2

2024-01-3118:23

Investigating Injustices in the Journal's History

2024-01-1721:45

Covid Update

2023-12-2020:39

Is Xenotransplantation Ready for Prime Time?

2023-12-0623:41

Alzheimer’s Update, Part 2

2023-11-2227:00

Alzheimer’s Update, Part 1

2023-11-0828:14

00:00

CAR T-Cells and Safety Signals

#box-pro-ellipsis-175978118146626{-webkit-line-clamp:2;}CAR T-Cells and Safety Signals

CAR T-Cells and Safety Signals

NEJM Group

CAR T-Cells and Safety Signals